24/7 Market News Snapshot 02 October, 2024 – Processa Pharmaceuticals, Inc. Common (NASDAQ:PCSA)

October 2, 2024

DENVER, Colo., 02 October, 2024 (247marketnews.com) – (NASDAQ:PCSA) are discussed in this article.
Processa Pharmaceuticals, Inc. (PCSA) is garnering significant investor interest as it experiences remarkable stock performance, currently trading at $1.694 after an impressive 27.48% increase since opening at $1.30. This surge is attributed to robust trading volume, reaching 698.88K shares, reflecting heightened confidence in the company’s future prospects as it advances its clinical programs.

In a noteworthy development, Processa has initiated patient dosing in its Phase 2 clinical trial for NGC-Cap, a promising new therapy targeting advanced or metastatic breast cancer. This adaptive study aims to evaluate the safety and efficacy of NGC-Cap in comparison to the FDA-approved treatment, capecitabine. The successful dosing of the first patient marks a pivotal step in the clinical development of this innovative therapy.

Dr. David Young, President of Research and Development at Processa, expressed enthusiasm regarding this milestone, affirming the company’s dedication to providing improved treatment options for cancer patients. He highlighted that the trial builds on encouraging outcomes from their Phase 1b study, as they seek to uncover the therapeutic potential of NGC-Cap.

The Phase 2 trial, identified as NCT06568692, is set to encompass 60 to 90 participants across multiple international sites. Its design emphasizes finding optimal dosage levels while adhering to FDA’s Project Optimus Initiative. By studying two dosing regimens of NGC-Cap alongside capecitabine monotherapy, Processa aims to revolutionize cancer treatment strategies, enhancing patient safety and treatment efficacy.

Given the alarming statistics surrounding breast cancer, which accounted for over 2 million diagnoses in 2022, the urgency for innovative therapeutic options is more pressing than ever. Processa’s strategic approach, combining its irreversible DPD enzyme inhibitor PCS6422 with low doses of capecitabine, aims to minimize side effects while maximizing the effectiveness against tumor cells. As the trial progresses, interim analysis results are anticipated in mid-2025, offering hope and potential advancements in the fight against metastatic breast cancer.

Related news for (PCSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.